SalaryGuide
AboutPricingFor Employers

Marketing jobs

3 marketing jobs

Haemonetics logo
6 days ago

Manager, Product Marketing

Haemonetics

Chicago, IL (On-site)Full time$104K/yr – $176K/yr
Haemonetics logo
2 months ago

Senior Manager, Marketing (US and Canada)

Haemonetics

Boston, MA (On-site)Full time$124K/yr – $212K/yr
Haemonetics logo
4 months ago

VP of Global Marketing, Interventional Technologies

Haemonetics

USA (Remote)Full time$210K/yr – $357K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

3 jobs
Haemonetics logo

Manager, Product Marketing

Haemonetics

Chicago, IL (On-site)

$104K/yr - $176K/yrIn-houseFull-timeManager4+ years exp.
6 days ago
Haemonetics logo

Senior Manager, Marketing (US and Canada)

Haemonetics

Boston, MA (On-site)

$124K/yr - $212K/yrIn-houseFull-timeSenior level10+ years exp.
2 months ago
Haemonetics logo

VP of Global Marketing, Interventional Technologies

Haemonetics

USA (Remote)

$210K/yr - $357K/yrIn-houseFull-timeSenior level10+ years exp.
4 months ago
Haemonetics logo
Haemonetics

Manager, Product Marketing

Chicago, IL (On-site)

$104K/yr – $176K/yrManager4+ years expFull time

Posted 6 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own downstream marketing strategy and commercial content for the IVT franchise, lead launch planning, field feedback, and regional adaptation to drive compelling downstream messaging.

  • Oversee content strategy and enablement across regions
  • Collaborate with Product Management to translate clinical data into market-ready messaging

Job Description

Responsibilities

  • Own downstream marketing strategy and commercial content for the IVT franchise, ensuring alignment with upstream product management, clinical marketing, and commercial priorities across regions.
  • Create and execute differentiated promotional and educational content and programs for the IVT franchise, optimizing channel mix across sales tools, events, and paid and owned media.
  • Drive launch planning and execution for IVT product label expansions and new indications, from brief through Agile review to full field deployment.
  • Conduct market analysis and competitive intelligence for the venous closure segment, generating insights to inform IVT strategy and messaging.
  • Monitor IVT product performance and gather field and customer feedback, partnering with Product Management on product improvements while ensuring regulatory compliance.
  • Own conference content strategy and product demo approach for IVT in partnership with Marketing Communications.
  • Lead voice of sales program for IVT, capturing structured field feedback on content gaps, competitive dynamics, and unmet commercial needs; translate insights into actionable marketing improvements.
  • Partner closely with Product Management to ensure commercial readiness at every stage of the IVT product lifecycle, translating clinical evidence, product specifications, and market insights into compelling downstream messaging and field-ready content.
  • Partner with international commercial and marketing teams to adapt IVT core content and messaging for regional market requirements and support regional go-to-market execution.
  • Maintain effective relations with both internal and external customers.

Requirements

  • Bachelor’s Degree B.S.
  • 4+ years Product marketing or downstream marketing experience in medical device Required
  • Other Demonstrated track record of leading product launches in a regulated environment, including content development and Agile/MLR review processes Required
  • Other Prior people management experience with a record of developing high-performing marketing talent Required
  • Other Experience marketing interventional cardiology, vascular, or structural heart products Preferred
  • Strong commercial storytelling skills; ability to translate complex clinical data into crisp, field-ready messaging Proficient
  • Proficiency in launch planning and cross-functional program management Proficient
  • Experience building and managing agency relationships and marketing budgets Proficient
  • Competitive intelligence development and sales enablement content creation Proficient
  • Strong executive communication and presentation skills Proficient

Preferred

  • Experience marketing interventional cardiology, vascular, or structural heart products Preferred

Benefits

  • In addition to compensation, the Company offers a competitive suite of benefits to its employees, including without limitation, a 401(k) with up to a 6% employer match and no vesting period, an employee stock purchase plan, “flexible time off” for salaried employees and, for hourly employees, accrual of three to five weeks’ vacation annually (based on tenure), accrual of up to 64 hours (annually) of paid sick time, paid and/or floating holidays, parental leave, short- and long-term disability insurance, tuition reimbursement, and/or health and welfare benefits.
  • Depending on your location, you may be eligible for more detailed information related to the compensation and benefits related to this job posting.
Haemonetics logo

Haemonetics

4.2 Glassdoor

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Founded in 1971
Boston, Massachusetts, USA
2.5K employees (68 in marketing)
www.haemonetics.com
88% recommend to a friend
78% CEO approval

Traffic Signals

Monthly Visitors
39.8K
Monthly Google Ads Budget
$29
Traffic Source Mix
Search
48.4%
Direct
37.8%
Referral
9.6%
Social
1.7%
Paid
2.2%

Headcount Trend

Current headcount: ~2.5K

Marketing Team

Marketing Team Size
57 (2% of company)
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$1.7B
Last Raise
$600M
Post IPO Debt, 2 years ago

Funding History

  • May 2024
    Post IPO Debt • $600M
  • Mar 2021
    Post IPO Equity • $435M
  • May 2019
    Post IPO Equity • $10M

Recent News

Haemonetics price target raised to $90 from $75 at BofA
Dec 8, 2025 • TipRanks
BofA Securities Maintains Haemonetics(HAE.US) With Hold Rating, Raises Target Price to $90
Dec 8, 2025 • 富途牛牛
Haemonetics (HAE): Reassessing Valuation After a 55% Three-Month Share Price Surge
Dec 8, 2025 • simplywall.st
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Dec 6, 2025 • sharewise.com
Should You Be Adding Haemonetics (NYSE:HAE) To Your Watchlist Today?
Dec 6, 2025 • Yahoo Finance
Capital Fund Management S.A. Makes New $995,000 Investment in Haemonetics Corporation $HAE
Dec 6, 2025 • Defense World
Haemonetics Corporation (NYSE:HAE) Enhances Medical Innovation
Dec 6, 2025 • Kalkine Media
Haemonetics stock hits 52-week high at $85.07 By Investing.com
Dec 5, 2025 • Investing.com Canada
Haemonetics leverages insights from MassWomen conference
Dec 5, 2025 • Traders Union
Boston Partners Buys 11,738 Shares of Haemonetics Corporation $HAE
Nov 29, 2025 • MarketBeat
Q1 EPS Estimates for Haemonetics Boosted by Zacks Research
Nov 28, 2025 • MarketBeat
What risks investors should watch in Haemonetics Corporation stock - Portfolio Risk Summary & Fast Moving Market Watchlists
Nov 27, 2025 • BỘ NỘI VỤ
Q3 EPS Estimates for Haemonetics Decreased by Zacks Research
Nov 27, 2025 • MarketBeat
Is There Opportunity in Haemonetics After Shares Surge 57% on Expansion News?
Nov 27, 2025 • simplywall.st
Haemonetics Reaches Analyst Target Price
Nov 26, 2025 • Nasdaq
Haemonetics stock holds Buy rating at BTIG on plasma segment strength
Nov 21, 2025 • Investing.com UK
BTIG Reiterates Haemonetics (HAE) Buy Recommendation
Nov 21, 2025 • Nasdaq
Haemonetics (HAE) Price Target Increased by 11.07% to 88.03
Nov 17, 2025 • Nasdaq
Interpreting Haemonetics (HAE) International Revenue Trends
Nov 17, 2025 • Yahoo Finance
Haemonetics Hits 80-Plus Relative Strength Rating Benchmark
Nov 14, 2025 • Investor's Business Daily
Raymond James raises Haemonetics stock price target to $90 on strong results
Nov 14, 2025 • Investing.com
Haemonetics (HAE): Assessing Valuation After Profit Beat and Completion of Major Buyback
Nov 13, 2025 • simplywall.st
5 Insightful Analyst Questions From Haemonetics’s Q3 Earnings Call
Nov 12, 2025 • Yahoo Finance
Haemonetics Shows Rising Relative Strength; Still Shy Of Key Threshold
Nov 11, 2025 • Investor's Business Daily
Key metrics from Haemonetics Corporation’s quarterly data - Weekly Trade Report & Low Risk High Reward Trade Ideas
Nov 10, 2025 • newser.com
SG Capital Dumps Nearly 732,000 Haemonetics Shares Worth $59.1 Million
Nov 8, 2025 • The Globe and Mail
SG Capital Dumps Nearly 732,000 Haemonetics Shares Worth $59.1 Million
Nov 8, 2025 • The Motley Fool
Will Haemonetics’ (HAE) Margin Gains and Upbeat Guidance Recast Its Long-Term Growth Narrative?
Nov 8, 2025 • simplywall.st
A Quick Look at Today's Ratings for Haemonetics(HAE.US), With a Forecast Between $75 to $90
Nov 8, 2025 • 富途牛牛
Haemonetics Corporation (NYSE:HAE) Q2 2026 Earnings Call Transcript
Nov 8, 2025 • Insider Monkey
Can Haemonetics' (HAE) Rising Profits Offset Revenue Headwinds in Its Competitive Strategy?
Nov 8, 2025 • Yahoo Finance
Needham Maintains Haemonetics (HAE) Buy Recommendation
Nov 8, 2025 • Nasdaq
Why Haemonetics Stock Was on Fire Thursday
Nov 7, 2025 • The Motley Fool
Why Haemonetics Stock Jumped 30%?
Nov 7, 2025 • Trefis
Haemonetics Is Still Undervalued, Even After The Rally (NYSE:HAE)
Nov 7, 2025 • Seeking Alpha
Haemonetics (NYSE:HAE) Shares Gap Up Following Strong Earnings
Nov 7, 2025 • Defense World
A Piece Of The Puzzle Missing From Haemonetics Corporation's (NYSE:HAE) 36% Share Price Climb
Nov 7, 2025 • simplywall.st
Haemonetics Reports Improved Profitability Amid Revenue Decline
Nov 7, 2025 • The Globe and Mail
A Piece Of The Puzzle Missing From Haemonetics Corporation's (NYSE:HAE) 36% Share Price Climb
Nov 7, 2025 • Sahm
Haemonetics Taking Prudent View on Guidance After Plasma Recovery, BofA Says
Nov 7, 2025 • marketscreener.com
Haemonetics Reports Improved Profitability Amid Revenue Decline
Nov 7, 2025 • TipRanks
BTIG Maintains Haemonetics (HAE) Buy Recommendation
Nov 7, 2025 • Nasdaq
Haemonetics: Fiscal Q2 Earnings Snapshot
Nov 6, 2025 • Connecticut Post
Haemonetics Corp (HAE) Q2 2026 Earnings Call Highlights: Strong Plasma Growth and Margin ...
Nov 6, 2025 • Yahoo Finance
Why Are Haemonetics (HAE) Shares Soaring Today
Nov 6, 2025 • Yahoo Finance
Haemonetics (HAE) Reports Q2 Earnings: What Key Metrics Have to Say
Nov 6, 2025 • Yahoo Finance
Haemonetics Corporation (HAE) Q2 FY2026 earnings call transcript
Nov 6, 2025 • Yahoo Finance
Haemonetics Q2 Profit Climbs, Lifts FY26 Adj. EPS View; Stock Up
Nov 6, 2025 • Nasdaq
Haemonetics earnings beat by $0.16, revenue topped estimates
Nov 6, 2025 • Investing.com
Haemonetics shares rise 3% as Q2 results top expectations, guidance raised
Nov 6, 2025 • Investing.com Australia
Haemonetics Corporation Q2 Fiscal 2026 Results
Nov 6, 2025 • TradingView
Haemonetics (NYSE: HAE) posts second-quarter FY2026 results on IR site; webcast 8 a.m. ET
Nov 6, 2025 • Stock Titan
Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Nov 6, 2025 • PR Newswire
Haemonetics (NYSE:HAE) Delivers Impressive Q3, Stock Jumps 12.8%
Nov 6, 2025 • Yahoo Finance
Haemonetics (NYSE:HAE) Delivers Impressive Q3, Stock Jumps 12.8%
Nov 6, 2025 • The Globe and Mail
Why Are Haemonetics (HAE) Shares Soaring Today
Nov 6, 2025 • TradingView
Haemonetics Faces Price Target Reduction Amid Financial Announcements
Nov 6, 2025 • timothysykes.com
Haemonetics stock rises as BTIG raises price target on strong earnings
Nov 6, 2025 • Investing.com
Haemonetics Reveals Fiscal Year 2026 Earnings Date Amid New Price Target Shift
Nov 6, 2025 • StocksToTrade
Haemonetics Corp Bottom Line Climbs In Q2
Nov 6, 2025 • Nasdaq
Haemonetics: Fiscal Q2 Earnings Snapshot
Nov 6, 2025 • marketscreener.com
Haemonetics Corp (HAE) Q2 2026 Earnings Call Highlights: Strong
Nov 6, 2025 • GuruFocus
Automated trading signals detected on Haemonetics Corporation - Weekly Investment Recap & Smart Swing Trading Alerts
Nov 6, 2025 • newser.com
Using AI based signals to follow Haemonetics Corporation - Weekly Market Summary & Low Drawdown Investment Ideas
Nov 5, 2025 • newser.com
Haemonetics (HAE): Evaluating Valuation After Earnings Beat and Ongoing Competitive Pressures
Nov 5, 2025 • simplywall.st
Haemonetics Q2 2026 Earnings Preview
Nov 5, 2025 • MSN
What To Expect From Haemonetics’s (HAE) Q3 Earnings
Nov 5, 2025 • Yahoo Finance
Haemonetics Corporation (HAE) is Navigating Challenges Through Earnings Growth
Nov 4, 2025 • Yahoo Finance
Haemonetics Corporation (HAE) is Navigating Challenges Through Earnings Growth
Nov 4, 2025 • Insider Monkey
Haemonetics Q2 FY26 Earnings: A Critical Juncture for the Stock
Nov 4, 2025 • AD HOC NEWS
Should You Hold Haemonetics Corporation (HAE)?
Nov 3, 2025 • Yahoo Finance
How Recent Developments Are Shaping the Haemonetics Investment Story
Oct 28, 2025 • Yahoo Finance
Haemonetics (HAE): Buy, Sell, or Hold Post Q2 Earnings?
Oct 27, 2025 • Yahoo Finance
Haemonetics (HAE): Buy, Sell, or Hold Post Q2 Earnings?
Oct 27, 2025 • The Globe and Mail
Riverwater Partners LLC Sells 5,091 Shares of Haemonetics Corporation $HAE
Oct 27, 2025 • MarketBeat
Can Haemonetics' (HAE) Surprise Revenue Beat Offset Sector Headwinds in the Long Run?
Oct 23, 2025 • simplywall.st
Unpacking Q2 Earnings: Haemonetics (NYSE:HAE) In The Context Of Other Medical Devices & Supplies - Specialty Stocks
Oct 20, 2025 • Yahoo Finance
Medical Devices & Supplies - Specialty Stocks Q2 Results: Benchmarking Haemonetics (NYSE:HAE)
Oct 19, 2025 • Yahoo Finance
How Will Weak Organic Sales Shape Haemonetics’ (HAE) Growth Strategy and Future Outlook?
Oct 16, 2025 • Yahoo Finance
Assessing Haemonetics After Recent Regulatory Approval and a 34% Decline in 2025
Oct 15, 2025 • Yahoo Finance
Can volume confirm reversal in Haemonetics Corporation - 2025 Earnings Surprises & Long-Term Investment Growth Plans
Oct 11, 2025 • newser.com
Risk vs reward if holding onto Haemonetics Corporation - 2025 Big Picture & Long-Term Growth Stock Strategies
Oct 11, 2025 • newser.com
Haemonetics (HAE): Analyst Downgrades Spark New Discussion on Valuation and Future Growth Potential
Oct 10, 2025 • simplywall.st
Dentsply Sirona, Acadia Healthcare, and Haemonetics Stocks Trade Down, What You Need To Know
Oct 10, 2025 • Yahoo Finance
Haemonetics (NYSE:HAE) Receives Hold (C-) Rating from Weiss Ratings
Oct 9, 2025 • MarketBeat
Haemonetics FY2028 EPS Forecast Decreased by Zacks Research
Oct 9, 2025 • Defense World
FY2028 EPS Estimates for Haemonetics Cut by Zacks Research
Oct 8, 2025 • MarketBeat
Haemonetics (NYSE:HAE) Price Target Cut to $64.00 by Analysts at Citigroup
Oct 8, 2025 • Defense World
Q1 EPS Estimates for Haemonetics Cut by Zacks Research
Oct 8, 2025 • Defense World
Citigroup Maintains Haemonetics (HAE) Buy Recommendation
Oct 8, 2025 • Nasdaq
Citigroup Lowers Haemonetics (NYSE:HAE) Price Target to $64.00
Oct 7, 2025 • MarketBeat
Q1 EPS Estimates for Haemonetics Decreased by Zacks Research
Oct 7, 2025 • MarketBeat
Citigroup Lowers Price Target for Haemonetics (HAE) to $64.00 | HAE Stock News
Oct 7, 2025 • GuruFocus
Hunter Perkins Capital Management LLC Acquires Shares of 7,100 Haemonetics Corporation $HAE
Oct 6, 2025 • MarketBeat
What the Recent FDA Plasma Guidance Means for Haemonetics Investors in 2025
Oct 4, 2025 • simplywall.st
Haemonetics (NYSE:HAE) Reaches New 12-Month Low - Here's What Happened
Oct 3, 2025 • MarketBeat
Is Haemonetics (HAE) Undervalued? A Fresh Look at the Company’s Current Valuation
Oct 3, 2025 • simplywall.st
Haemonetics (HAE): Evaluating Valuation After Recent Share Price Weakness and Continued Earnings Growth
Oct 2, 2025 • Yahoo Finance
What Haemonetics (HAE)'s Exposure to Tariff Risks on Medical Device Imports Means for Shareholders
Sep 28, 2025 • simplywall.st
Haemonetics Poised for Recovery and Growth: Buy Rating Affirmed Amid Strategic Actions and Strong Segment Performance
Sep 23, 2025 • TipRanks